Provided by Tiger Trade Technology Pte. Ltd.

Genmab A/S

25.92
+0.10000.39%
Volume:224.37K
Turnover:5.85M
Market Cap:16.65B
PE:16.86
High:26.20
Open:26.15
Low:25.88
Close:25.82
52wk High:35.43
52wk Low:17.24
Shares:642.38M
Float Shares:635.00M
Volume Ratio:0.66
T/O Rate:0.04%
Dividend:- -
Dividend Rate:- -
EPS(TTM):1.54
EPS(LYR):1.54
ROE:17.53%
ROA:8.10%
PB:2.85
PE(LYR):16.86

Loading ...

Genmab A/S Stock Falls Friday, Underperforms Market

Dow Jones
·
Jan 03

Genmab Faces 'Transformative' Year Ahead With Pivotal Trial Readouts, Truist Securities Says

MT Newswires Live
·
Dec 31, 2025

Genmab A/S Stock Falls Monday, Underperforms Market

Dow Jones
·
Dec 30, 2025

Genmab Ending Development of Acasunlimab Cancer-Drug Candidate

Dow Jones
·
Dec 29, 2025

Genmab Discontinues Development of Tumor Treatment Acasunlimab

MT Newswires Live
·
Dec 29, 2025

Genmab A/S Stock Rises Monday, Outperforms Market

Dow Jones
·
Dec 23, 2025

Genmab A/S Stock Rises Wednesday, Outperforms Market

Dow Jones
·
Dec 18, 2025

Genmab A/S Stock Falls Monday, Outperforms Market

Dow Jones
·
Dec 16, 2025

Genmab A/S Stock Falls Wednesday, Underperforms Market

Dow Jones
·
Dec 11, 2025

Genmab Epcoritamab Achieves Up to 73% Complete Response Across Richter Transformation Trial Arms

MT Newswires Live
·
Dec 09, 2025

Genmab A/S Stock Rises Monday, Outperforms Market

Dow Jones
·
Dec 09, 2025

Genmab : Leerink Partners Raises Target Price to $38 From $34

THOMSON REUTERS
·
Dec 08, 2025

Genmab A/S Stock Falls Wednesday, Underperforms Market

Dow Jones
·
Dec 04, 2025

Genmab's Cervical Cancer Drug Gets UK Regulatory Approval

MT Newswires Live
·
Dec 03, 2025

Genmab A/S Stock Rises Monday, Outperforms Market

Dow Jones
·
Dec 02, 2025

Genmab A/S Stock Rises Wednesday, Outperforms Market

Dow Jones
·
Nov 27, 2025

Genmab A/S Stock Rises Friday, Outperforms Market

Dow Jones
·
Nov 22, 2025

Genmab (GMAB) Receives a Buy from Guggenheim

TIPRANKS
·
Nov 21, 2025

Truist Financial Sticks to Their Buy Rating for Genmab (GMAB)

TIPRANKS
·
Nov 19, 2025

H.C. Wainwright Sticks to Its Buy Rating for Genmab (GMAB)

TIPRANKS
·
Nov 19, 2025